Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fenebrutinib
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fenebrutinib is an investigational oral, reversible and non-covalent Bruton's tyrosine kinase (BTK) inhibitor developed by Genentech (a member of the Roche Group). It selectively blocks BTK, a key enzyme involved in B-cell development and activation as well as the activation of myeloid lineage cells such as macrophages and microglia. By inhibiting both B-cell and microglia activation, fenebrutinib aims to reduce disease activity and disability progression in autoimmune diseases. It is currently being evaluated primarily for multiple sclerosis (MS), including relapsing MS (RMS) and primary progressive MS (PPMS), with ongoing Phase III clinical trials. Fenebrutinib is notable for being a highly selective reversible BTK inhibitor[3][7].
- Brand names
- fenebrutinib
- Other names
- fenebrutinib
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on fenebrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fenebrutinib.